[go: up one dir, main page]

ATE210458T1 - Modifizierter faktor vii zur hemmung der vaskulären restenosis und thrombozytenablagerung - Google Patents

Modifizierter faktor vii zur hemmung der vaskulären restenosis und thrombozytenablagerung

Info

Publication number
ATE210458T1
ATE210458T1 AT94918092T AT94918092T ATE210458T1 AT E210458 T1 ATE210458 T1 AT E210458T1 AT 94918092 T AT94918092 T AT 94918092T AT 94918092 T AT94918092 T AT 94918092T AT E210458 T1 ATE210458 T1 AT E210458T1
Authority
AT
Austria
Prior art keywords
factor vii
thrombocyte
deposition
modified factor
vascular restenosis
Prior art date
Application number
AT94918092T
Other languages
English (en)
Inventor
Kathleen L Berkner
Lars Christian Petersen
Charles E Hart
Original Assignee
Zymogenetics Inc
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Novo Nordisk As filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE210458T1 publication Critical patent/ATE210458T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94918092T 1993-05-21 1994-05-23 Modifizierter faktor vii zur hemmung der vaskulären restenosis und thrombozytenablagerung ATE210458T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6572593A 1993-05-21 1993-05-21
PCT/US1994/005779 WO1994027631A1 (en) 1993-05-21 1994-05-23 Modified factor vii

Publications (1)

Publication Number Publication Date
ATE210458T1 true ATE210458T1 (de) 2001-12-15

Family

ID=22064676

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94918092T ATE210458T1 (de) 1993-05-21 1994-05-23 Modifizierter faktor vii zur hemmung der vaskulären restenosis und thrombozytenablagerung

Country Status (11)

Country Link
EP (1) EP0699075B1 (de)
JP (1) JPH08510746A (de)
AT (1) ATE210458T1 (de)
AU (1) AU703110B2 (de)
CA (1) CA2162726A1 (de)
DE (1) DE69429429T2 (de)
DK (1) DK0699075T3 (de)
ES (1) ES2169074T3 (de)
HU (1) HU219682B (de)
PT (1) PT699075E (de)
WO (1) WO1994027631A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
NZ521257A (en) 2000-02-11 2004-10-29 Maxygen Aps Factor VII or VIIa-like molecules
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
BR0113854A (pt) 2000-09-13 2004-07-06 Novo Nordisk As Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal
AU2001287550B2 (en) * 2000-09-13 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor VII variants
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
HUP0401124A3 (en) 2001-03-22 2006-01-30 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP1443956A2 (de) * 2001-11-02 2004-08-11 Novo Nordisk Health Care AG Verwendung des gewebefaktor-agonisten oder gewebefaktor-antagonisten zur behandlung von erkrankungen im zusammenhang mit apoptose
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
CN1607958A (zh) 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
JP2005523723A (ja) 2002-04-30 2005-08-11 マキシゲン ホルディングス リミテッド 第ＶＩＩ因子または第ＶＩＩａ因子のポリペプチド変種
JP4648002B2 (ja) 2002-06-21 2011-03-09 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの安定化された固体組成物
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
DK1549677T3 (da) * 2002-09-30 2011-07-18 Bayer Healthcare Llc FVII- eller FVIIa-varianter med forøget koagulationsaktivitet
AU2003275947A1 (en) * 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
ES2386010T3 (es) 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CN1780638B (zh) 2003-05-23 2010-04-14 诺和诺德医疗保健公司 氧化硅涂层玻璃作为容器内壁材料的用途及以该材料作内壁的容器
KR101191779B1 (ko) 2003-06-19 2013-01-14 맥시겐 홀딩스 엘티디 인자 ⅶ 또는 ⅶ에이 지엘에이 도메인 변종들
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
KR20120104619A (ko) 2003-08-14 2012-09-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
EP2392655A3 (de) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Gerinnungsfaktor VII Polypeptide
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2006035060A2 (en) * 2004-09-29 2006-04-06 Novo Nordisk Health Care Ag Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material
CA2585758C (en) 2004-10-29 2017-08-01 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
EP2626079A3 (de) 2008-02-27 2014-03-05 Novo Nordisk A/S Konjugierte Faktor-VIII-Moleküle
US20190015532A1 (en) 2016-01-15 2019-01-17 Rigshospitalet Quantitative pet imaging of tissue factor expression using 18f-labled active site inhibited factor vii
US20190358351A1 (en) 2016-11-17 2019-11-28 Minerva Imaging Aps 177-lu labeled active site inhibited factor vii

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE180834T1 (de) * 1990-01-29 1999-06-15 Zymogenetics Inc Antikoagulierende proteine
EP1479395A1 (de) * 1991-02-28 2004-11-24 Novo Nordisk A/S Modifizierter Faktor VII

Also Published As

Publication number Publication date
JPH08510746A (ja) 1996-11-12
PT699075E (pt) 2002-05-31
ES2169074T3 (es) 2002-07-01
AU6956094A (en) 1994-12-20
DE69429429T2 (de) 2002-05-16
DE69429429D1 (de) 2002-01-24
AU703110B2 (en) 1999-03-18
HU219682B (hu) 2001-06-28
WO1994027631A1 (en) 1994-12-08
EP0699075A1 (de) 1996-03-06
HU9503312D0 (en) 1996-01-29
EP0699075B1 (de) 2001-12-12
CA2162726A1 (en) 1994-12-08
HUT73329A (en) 1996-07-29
DK0699075T3 (da) 2002-03-11

Similar Documents

Publication Publication Date Title
ATE210458T1 (de) Modifizierter faktor vii zur hemmung der vaskulären restenosis und thrombozytenablagerung
MX9702951A (es) Factor vii modificado.
DE69233398D1 (de) Modifizierter faktor-vii
HUP0003077A2 (hu) Módosított VII faktor
PT96103A (pt) Processo para a preparacao de proteinas fibrinoliticas e anti-tromboticas activaveis
DE69334250D1 (de) Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
ATE177752T1 (de) Neue inhibitoren von faktor xa
MXPA04004797A (es) Indol-2-carboxamidas como inhibidores del factor xa.
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
ATE354591T1 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
DE69837923D1 (de) Bestandteil von bromelain
DE69317343D1 (de) Verwendung eines direkten Inhibitors von Thrombin zur Herstellung eines Arzneimittels mit thrombolytischer Aktivität
FI883730A0 (fi) Etrar och tioetrar med terapeutisk effekt, framstaellning av dessa och farmaceutiska sammansaettningar som innehaoller dem.
DE59709081D1 (de) Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung und Prävention der Alzheimer'schen Krankheit
ATE245983T1 (de) Inhibitoren der nuklearen lokalisierung von hiv

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee